Forbion raises in excess of €2 billion for two new funds
| Target: | Forbion |
| Date announced: | 2024-10-15 |
Forbion raises over €2 billion for two new funds, reaching €5 billion in assets under management
Forbion, a prominent global life sciences venture capital firm, has announced the successful raising of more than €2 billion ($2.2 billion) across two new funds: Forbion Growth Opportunities Fund III and Forbion Ventures Fund VII. The funds secured €1.2 billion and €890 million respectively, surpassing initial targets. This brings Forbion's total assets under management to €5 billion ($5.5 billion).
The fundraising, the firm's largest to date, will allow Forbion to expand its investments in life sciences companies, with plans to back approximately 15 portfolio companies per fund. Forbion's focus remains on identifying biopharma companies with groundbreaking therapies, particularly in Europe and North America. Recent exits, including several over $1 billion, underscore Forbion's strong performance in the sector.
Sander Slootweg, Managing Partner and co-founder of Forbion, expressed gratitude for investor confidence, noting the firm’s commitment to supporting innovative biotechs. General Partner Robbert van de Griendt highlighted the fundraising success despite challenging market conditions, citing strong historical returns and investor trust in Forbion's expertise.
With over 30 investment professionals and strategic partnerships with leading biotech service providers, Forbion continues to be a key player in advancing medical and biotech innovation.